Key result
Sepetaprost resulted in a numerically but not statistically significantly lower mean 24-h intraocular pressure at 3 months compared to latanoprost (MD -0.88 mmHg) in patients with primary open-angle glaucoma or ocular hypertension.
Why the study?
Understanding the 24-h efficacy and safety of sepetaprost versus latanoprost may delineate sepetaprost's future position in glaucoma treatment.
Does sepetaprost ophthalmic solution 0.002% reduce 24-h intraocular pressure compared to latanoprost 0.005% in adults with primary open-angle glaucoma or ocular hypertension?
RCT (n=33)
Single-blind
permuted-block randomization
Yes
Does sepetaprost ophthalmic solution 0.002% reduce 24-h intraocular pressure compared to latanoprost 0.005% in adults with primary open-angle glaucoma or ocular hypertension?
Mean Difference: -0.88 (95% CI -2.89–1.14)
p-value: p=>0.05
Sepetaprost did not demonstrate a statistically significant reduction in 24-hour intraocular pressure compared to latanoprost at 3 months, though numerical trends were observed in favor of sepetaprost.
Sepetaprost shows no significant 24-h IOP advantage over latanoprost; leaves open its therapeutic role and requires larger confirmatory trials.
Understanding the 24-h efficacy and safety of a novel therapy option, sepetaprost ophthalmic solution 0.002% vs. latanoprost ophthalmic solution 0.005%, may delineate its future position in glaucoma treatment. In this exploratory study (EudraCT 2020-004836-93), adults with primary open-angle glaucoma (POAG) or ocular hypertension (OHT) were randomized to sepetaprost or latanoprost for 3 months following a ≤ 35-day screening period. The primary endpoint was mean 24-h intraocular pressure (IOP) at month 3 with sepetaprost vs. latanoprost. Safety outcomes included rate of adverse events (AEs). Overall, 33 participants received treatment (sepetaprost, n = 17; latanoprost, n = 16). Mean 24-h IOP was numerically lower with sepetaprost vs. latanoprost at month 3 (− 0.88 mmHg; 95% confidence interval [CI] − 2.89, 1.14; not statistically significant at the 0.05 level [NS]). Mean change from baseline in IOP at month 3 ranged from − 5.63 to − 7.00 mmHg for sepetaprost and − 3.84 to − 6.66 mmHg for latanoprost. Lower nocturnal IOP was observed with sepetaprost vs. latanoprost at month 3 (− 1.61 mmHg difference; 95% CI − 4.05, 0.83; not statistically significant; however, the 90% CI was − 5.27, − 0.17 and therefore, nominal statistical significance was achieved at the 0.10 level). Mean difference between groups indicated similar, or numerically lower, IOP with sepetaprost at individual time points at week 6 and month 3. At 36 and 48 h following sepetaprost cessation, mean IOP was lower vs. baseline IOP at the same time points. AEs occurred in 13 (76.5%) vs. 11 (68.8%) participants treated with sepetaprost vs. latanoprost. In participants with POAG or OHT, mean 24-h IOP and nocturnal IOP at month 3 were consistently numerically lower with sepetaprost vs. latanoprost. Safety profiles were similar between groups. EudraCT 2020-004836-93. Glaucoma is an eye condition in which the nerve that connects the eye to the brain (the optic nerve) is damaged. This damage is often caused by a buildup of fluid, leading to high pressure within the eye (called intraocular pressure) and ocular hypertension. Primary open-angle glaucoma is a type of glaucoma that develops when the flow of fluid out of the eye is stopped by blocked drainage channels. Latanoprost is a drug that is widely used in eye drops to treat primary open-angle glaucoma and ocular hypertension, which lowers intraocular pressure by reducing the amount of fluid inside the eye. Sepetaprost is a new type of drug that lowers intraocular pressure by increasing the drainage of fluid from the eye. This study looked at the effect of sepetaprost compared with latanoprost on intraocular pressure throughout the day and night at 2 weeks, 6 weeks, and 3 months after starting treatment, in people with primary open-angle glaucoma and ocular hypertension. Any unwanted side effects were recorded throughout the study. This study showed that, compared with people treated with latanoprost, people treated with sepetaprost had on average lower intraocular pressure during the day, the night, and over the full 24-h period. Additionally, the number of participants who had side effects was similar with each drug; around 77% and 69% of people treated with sepetaprost and latanoprost, respectively. Most side effects affecting the eye were mild. These results suggest sepetaprost may be a promising treatment option for people with glaucoma or ocular hypertension.
No takes yet. Share an insight, caveat, or question.
Konstas et al. (2025) conducted an RCT in Primary open-angle glaucoma or ocular hypertension (n=33). Sepetaprost ophthalmic solution vs. Latanoprost ophthalmic solution 0.005% once daily was evaluated on Mean 24-h intraocular pressure (IOP) at month 3 (MD -0.88 mmHg, 95% CI -2.89, 1.14, p=>0.05). Sepetaprost resulted in a numerically but not statistically significantly lower mean 24-h intraocular pressure at 3 months compared to latanoprost (MD -0.88 mmHg) in patients with primary open-angle glaucoma or ocular hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: